Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Harvard Bioscience, Inc.

Harvard Bioscience, Inc.

HBIO

0.00

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ: HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.